Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
5e5 of Anti-CLEC12A/CLL-1 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human CLEC12A Protein, His Tag, premium grade (Cat. No. CLA-HA246) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
5e5 of anti-CLEC12A / CLL-1 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human CLEC12A, His Tag (Cat. No. CLA-HA248) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
Immobilized Biotinylated Human CLEC12A Protein, Avitag,His Tag, premium grade (Cat. No. CLA-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-Human CLEC12A Antibody, Human IgG1 with a linear range of 0.1-0.8 ng/mL (QC tested).
The purity of Human CLEC12A, Fc Tag (Cat. No. CLA-H5266) is more than 90% and the molecular weight of this protein is around 125-140 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
| Anti-CLL1 CAR-T (Guangzhou Bio-Gene) | BG-1805; BG1805 | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Leukemia; Leukemia, Myeloid, Acute | Details |
| Anti-CLL1 CAR T cell therapy(Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia, Myeloid, Acute | Details | |
| ICG-136 | ICG-136; 123b-33bcCAR | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Leukemia, Myeloid, Acute | Details |
| CLL-1.CAR T cell therapy (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Myeloid, Acute | Details | |
| DCLL-9718S | DCLL-9718S; MCLL-0517A; RG-6109 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Leukemia, Myeloid, Acute | Details |
| Anti-CLL-1 CAR NK cells Therapy(Shanghai General Hospital) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd, The 920th Hospital Of Joint Logistics Support Force Of PLA | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CLL1 CAR-NK cell (Zhejiang University/Hangzhou Qihangene Biotech) | Phase 1 Clinical | Zhejiang University, Hangzhou Qihan Jiyin Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| CD33/CLL1 dual CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co Ltd | Neoplasm, Residual; Leukemia, Myeloid, Acute | Details | |
| CD371-YSNVZ-IL18 CAR T cells therapy | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Leukemia, Myeloid, Acute | Details | |
| CLL-1/CD33 Targeted LCAR-AMDR Cells（Nanjing Legend Biotechnology） | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| IBR-733 | IBR-733; IBR733 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details |
| CLL1 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CLL1+CD33 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CLL1 CAR T-cell Therapy(Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33/CLL1 CAR-NK Cell Therapy | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details | |
| KITE-222 | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Legend Biotech Corp | Leukemia, Promyelocytic, Acute | Details | |
| Tepoditamab | MCLA-117 | Phase 1 Clinical | Pharmaceutical Research Associates, Institute Gustave-Roussy, Merus Nv, Vu University Medical Center, Lgc | Leukemia, Myeloid, Acute | Details |
| CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
| Anti-CLL1 CAR-T (Guangzhou Bio-Gene) | BG-1805; BG1805 | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Leukemia; Leukemia, Myeloid, Acute | Details |
| Anti-CLL1 CAR T cell therapy(Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia, Myeloid, Acute | Details | |
| ICG-136 | ICG-136; 123b-33bcCAR | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Leukemia, Myeloid, Acute | Details |
| CLL-1.CAR T cell therapy (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Myeloid, Acute | Details | |
| DCLL-9718S | DCLL-9718S; MCLL-0517A; RG-6109 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Leukemia, Myeloid, Acute | Details |
| Anti-CLL-1 CAR NK cells Therapy(Shanghai General Hospital) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd, The 920th Hospital Of Joint Logistics Support Force Of PLA | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CLL1 CAR-NK cell (Zhejiang University/Hangzhou Qihangene Biotech) | Phase 1 Clinical | Zhejiang University, Hangzhou Qihan Jiyin Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| CD33/CLL1 dual CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co Ltd | Neoplasm, Residual; Leukemia, Myeloid, Acute | Details | |
| CD371-YSNVZ-IL18 CAR T cells therapy | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Leukemia, Myeloid, Acute | Details | |
| CLL-1/CD33 Targeted LCAR-AMDR Cells（Nanjing Legend Biotechnology） | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| IBR-733 | IBR-733; IBR733 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details |
| CLL1 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CLL1+CD33 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CLL1 CAR T-cell Therapy(Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33/CLL1 CAR-NK Cell Therapy | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details | |
| KITE-222 | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Legend Biotech Corp | Leukemia, Promyelocytic, Acute | Details | |
| Tepoditamab | MCLA-117 | Phase 1 Clinical | Pharmaceutical Research Associates, Institute Gustave-Roussy, Merus Nv, Vu University Medical Center, Lgc | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.
A-Z
